Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC.

ABSTRACT:

Background

While neoadjuvant chemoimmunotherapy (NACI) improves outcomes in resectable non-small cell lung cancer (NSCLC), a significant subset of patients exhibits innate resistance. Biomarkers predicting response are urgently needed. Given the central role of antigen processing in immunotherapy efficacy, we investigated key immunoproteasome components-LMP2 (PSMB9), PSME1, and PSME2-as potential tissue-based biomarkers for NACI response and survival.

Methods

Potential biomarker genes were identified through systematic literature review of NSCLC immunotherapy transcriptomic datasets. Candidate genes underwent validation in public databases (GEO, TCGA) via differential expression and Kaplan-Meier survival analysis. Protein expression of LMP2, PSME1, and PSME2 was assessed by

SUBMITTER: Xie R 

PROVIDER: S-EPMC12479417 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature